- Home
- FG vs ACAD Comparison
FG vs ACAD Comparison
Compare FG & ACAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FG
- ACAD
- Stock Information
- Founded
- FG 1959
- ACAD 1993
- Country
- FG United States
- ACAD United States
- Employees
- FG N/A
- ACAD N/A
- Industry
- FG Life Insurance
- ACAD Biotechnology: Pharmaceutical Preparations
- Sector
- FG Finance
- ACAD Health Care
- Exchange
- FG Nasdaq
- ACAD Nasdaq
- Market Cap
- FG 4.0B
- ACAD 4.1B
- IPO Year
- FG N/A
- ACAD 2004
- Fundamental
- Price
- FG $32.62
- ACAD $24.09
- Analyst Decision
- FG Hold
- ACAD Buy
- Analyst Count
- FG 2
- ACAD 21
- Target Price
- FG $41.00
- ACAD $29.10
- AVG Volume (30 Days)
- FG 158.3K
- ACAD 1.7M
- Earning Date
- FG 11-06-2025
- ACAD 11-05-2025
- Dividend Yield
- FG 3.06%
- ACAD N/A
- EPS Growth
- FG 3428.12
- ACAD 98.53
- EPS
- FG 3.42
- ACAD 1.54
- Revenue
- FG $5,559,000,000.00
- ACAD $1,047,118,000.00
- Revenue This Year
- FG N/A
- ACAD $14.12
- Revenue Next Year
- FG $19.65
- ACAD $11.80
- P/E Ratio
- FG $9.53
- ACAD $15.57
- Revenue Growth
- FG N/A
- ACAD 12.69
- 52 Week Low
- FG $28.70
- ACAD $13.40
- 52 Week High
- FG $50.75
- ACAD $26.65
- Technical
- Relative Strength Index (RSI)
- FG 64.79
- ACAD 61.73
- Support Level
- FG $29.56
- ACAD $22.00
- Resistance Level
- FG $33.59
- ACAD $23.58
- Average True Range (ATR)
- FG 0.93
- ACAD 1.03
- MACD
- FG 0.50
- ACAD 0.24
- Stochastic Oscillator
- FG 81.01
- ACAD 90.93
About FG F&G Annuities & Life Inc.
F&G Annuities & Life Inc is a provider of insurance solutions serving retail annuity and life customers as well as institutional clients. Through its insurance subsidiaries, including FGL Insurance and Fidelity & Guaranty Life Insurance Company of New York it markets a broad portfolio of deferred annuities (fixed indexed annuities (FIAs) and multi-year guarantee annuities (MYGAs) or other fixed rate annuities), immediate annuities, indexed universal life (IUL) insurance, funding agreements through funding agreement-backed notes (FABN) issuances and the Federal Home Loan Bank of Atlanta (FHLB)), and pension risk transfer (PRT) solutions.
About ACAD ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of medicines that address unmet medical needs in central nervous system (CNS) disorders and rare diseases. It has two core franchises in neuroscience and neuro-rare diseases. The neuroscience franchise is anchored by its commercial product NUPLAZID (pimavanserin), which is used for the treatment of hallucinations and delusions associated with Parkinson's Disease Psychosis (PDP). The neuro-rare disease franchise is anchored by the commercial product DAYBUE, which is used for the treatment of Rett syndrome. In addition, the company has various product candidates under development in different stages, including ACP-204, ACP-101, ACP-211, ACP-711, ACP-2591, etc.